Lilly’s CAR-T Kelonia deal cements Big Pharma’s in vivo push

The pharma giant’s second CAR-T deal this year, this one worth up to $7 billion, further solidifies what the industry sees as ...
Virginia Business

Lilly bets on next-generation cell therapy with $2.4B deal for Orna

Feb 9 (Reuters) – Eli Lilly will buy Orna Therapeutics for up to $2.4 billion in cash, gaining access to a technology that allows patients’ own cells to generate therapies inside the body, without the ...
FierceBiotech

Kite puts $1.64B on the line for Pregene’s in vivo CAR-Ts

Gilead Sciences' Kite Pharma is doubling down on in vivo CAR-T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. Kite has paid out $120 million ...
24/7 Wall St.

Bloom Energy Jumps 14%, Oracle Rises 7% as Fuel Cell Deal Fuels AI Data Center Power Race

Bloom Energy (NYSE:BE) stock is up 14% in early trading today, and Oracle (NYSE:ORCL | ORCL Price Prediction) stock is up 7%, ...